A5068445918- Parathyroid Disorders and Treatments
- Magnesium in Health and Disease
- Biomedical Research and Pathophysiology
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Bone and Joint Diseases
- Nuclear Structure and Function
- Potassium and Related Disorders
- Nutrition and Health in Aging
- Hemoglobinopathies and Related Disorders
- Ion Transport and Channel Regulation
- Lipid metabolism and disorders
- Diabetes Management and Research
- Blood Pressure and Hypertension Studies
- Ion channel regulation and function
- Growth Hormone and Insulin-like Growth Factors
- Renal and related cancers
- Fibroblast Growth Factor Research
- Renal function and acid-base balance
- Genetic Syndromes and Imprinting
Instituto de Investigación Sanitaria del Principado de Asturias
2023
Universidad de Oviedo
2017-2021
ABSTRACT Background Bone fragility fractures are associated with high morbidity and mortality. This study analysed the association between current biochemical parameters of chronic kidney disease–mineral bone disorders (CKD-MBD) in COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) project. Methods is 3-year, multicentre, open cohort, prospective, observational carried out 6797 haemodialysis patients (227 centres from 20 European countries). The...
Abstract Background X-linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in PHEX gene leading tohypophosphatemia and high renal loss of phosphate. Rickets growth retardation are the major manifestations XLH children, but there broad phenotypic variability. Few publications have reported large series patients. Current data on clinical spectrum disease, correlation with underlying mutations, long-term outcome patients conventional treatment needed,...
X-linked hypophosphatemia (XLH) leads to growth retardation and bone deformities, which are not fully avoided by conventional treatment with phosphate vitamin D analogs. Pediatric patients have been treated hormone (GH), recent findings suggest that blocking fibroblast factor 23 actions may be the most effective therapy, but its effects on known. We here report effect of MAPK inhibition alone or associated GH plate structure young Hyp (the XLH animal model) mice. Untreated mice were severely...
An amendment to this paper has been published and can be accessed via the original article.
Abstract BACKGROUND X-Linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in PHEX gene leading to and high renal loss of phosphate. Rickets growth retardation are the major manifestations XLH children, but there broad phenotypic variability. Few publications have reported large series patients. Current data on clinical spectrum disease, correlation with underlying mutations, long-term outcome patients conventional treatment needed, particularly...
Abstract BACKGROUND X-Linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in PHEX gene leading tohypophosphatemia and high renal loss of phosphate. Rickets growth retardation are the major manifestations XLH children, but there broad phenotypic variability. Few publications have reported large series patients. Current data on clinical spectrum disease, correlation with underlying mutations, long-term outcome patients conventional treatment needed,...
Abstract BACKGROUND X-Linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in PHEX gene leading tohypophosphatemia and high renal loss of phosphate. Rickets growth retardation are the major manifestations XLH children, but there broad phenotypic variability. Few publications have reported large series patients. Current data on clinical spectrum disease, correlation with underlying mutations, long-term outcome patients conventional treatment needed,...